Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma


This is a Phase 1b open-label study of CPI-444, an oral, small molecule inhibitor targeting adenosine-2A receptors (A2AR), on safety/tolerability and efficacy as a single agent and in combination with daratumumab, a monoclonal antibody targeting CD38, in relapsed or refractory multiple myeloma.

SparkCures ID 1087
Trial Phase Phase 1
Enrollment 28 Patients
Trial Sponsors
  • Corvus Pharmaceuticals, Inc.
NCT Identifier


Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • Relapsed or refractory myeloma.
  • Must have been exposed to at least 2 cycles of an IMiD containing regimen and PI containing regimen and must be refractory to at least one of the two.
  • Must have completed and tolerated 2 cycles of daratumumab or other anti-CD38 targeting antibodies.
  • Active myeloma requiring systemic treatment.
  • Measurable disease per protocol.
  • ECOG performance status of 0 - 2.
  • Life expectancy of at least 3 months.

Exclusion Criteria:

  • POEMS syndrome; non-secretory myeloma (no measurable protein on sFLC assay); amyloidosis.
  • History of select prior malignancies.
  • Previous intolerance to daratumumab or any study drug.
  • Received an allogeneic stem cell transplant within 12 months, or an autologous stem cell transplant within 6 months, or have ongoing toxicity related to transplant.
  • Have an active infection or serious comorbid medical condition.
  • Any live attenuated vaccination against infectious diseases (e.g., influenza, varicella) within 4 weeks of initiation of study treatment; uncontrolled human immunodeficiency virus, or positive tests for hepatitis B or hepatitis C.
  • Female participants pregnant or breast-feeding.
  • Screening chemistry and blood counts within protocol limits
  • Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment or anticipation of need for systemic immunosuppressant medication during study treatment.

US Trial Locations

Accepting Patients

The following is a listing of trial locations that are open and accepting patients.



There are no resources, links or videos to display for this clinical trial.

Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message